Cardioprotective effects of the combined use of puerarin and Danshensu on acute ischemic myocardial injury in rats.
Ischemic heart diseases are the leading cause of death in both developed and developing countries over the past decades. The aim of this study was to investigate the cardioprotective effects of the complex preparation (called Shenge), made of puerarin and Danshensu, on acute ischemic myocardial injury in rats and its underlying mechanisms. The left anterior descending (LAD) coronary artery was occluded to induce myocardial ischemia in hearts of SD rats. Shenge was injected into the tail vein 15 min after occlusion at doses of 0, 30, 60 or 120 mg/kg. Then, the ST elevation was measured at 60, 120 and 240 min after Shenge administration. The infarct size, serum levels of creatine kinase isoenzyme-MB (CK-MB), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA), and the ST elevation were measured after the rats were killed. Shenge decreased the ST elevation induced by acute myocardial ischemia, reduced infarct size, serum levels of CK-MB, LDH and MDA and increased the serum activity of SOD in a dose-dependent manner. The combined use of puerarin and Danshensu at a ratio of 1:1 shows the most effective activity. In conclusion, Shenge exerts significant cardioprotective effects against acute ischemic myocardial injury in rats, likely through its antioxidant and antilipid peroxidation properties, and thus may be used as an effective and promising medicine for both prophylaxis and treatment of ischemic heart disease.
Wu
Limao
L
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Qiao
Hongxiang
H
Li
Yikui
Y
Li
Lianda
L
D000818:Animals; D002316:Cardiotonic Agents / Q000737:chemistry / Q000627:therapeutic use*; D004110:Diltiazem / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D007529:Isoflavones / Q000737:chemistry / Q000627:therapeutic use*; D007773:Lactates / Q000737:chemistry / Q000627:therapeutic use*; D008968:Molecular Conformation; D017202:Myocardial Ischemia / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014665:Vasodilator Agents / Q000737:chemistry / Q000494:pharmacology
D002316:Cardiotonic Agents; D004338:Drug Combinations; D007529:Isoflavones; D007773:Lactates; D014665:Vasodilator Agents; C035055:3,4-dihydroxyphenyllactic acid; D004110:Diltiazem; C033607:puerarin